BASKING RIDGE, N.J. & RAHWAY, N.J., May 29, 2025--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: ...

Patritumab deruxtecan, with or without letrozole, showed similar efficacy to chemotherapy in high-risk HR-positive, HER2-negative breast cancer, with lower severe side effects. The SOLTI VALENTINE ...

BASKING RIDGE, N.J. & RAHWAY, N.J., August 27, 2025--(BUSINESS WIRE)--The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational ...

Multi-year, multi-study collaboration includes two adaptive phase 2 trials with DS-1062 in lung cancer and patritumab deruxtecan (U3-1402) in breast cancer Program to focus on clinical and precision ...

Please provide your email address to receive an email when new articles are posted on . Patients who fail EGFR TKIs often receive platinum-based chemotherapy and subsequent salvage therapies, but PFS ...

Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with advanced EGFR-mutated non-small cell lung cancer ...

A single-arm phase 2 trial showed that patritumab deruxtecan (HER3-DXd) demonstrated meaningful clinical activity in pretreated patients with metastatic breast cancer and active brain metastases, ...

Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being developed jointly by Daiichi Sankyo and Merck ...